Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 8, 2010 - Issue 3
Submit an article Journal homepage
314
Views
61
CrossRef citations to date
0
Altmetric
Review

Potential of the β-glucans to enhance innate resistance to biological agents

Iain J Thompson Defence Science and Technology Laboratory, Porton Down, Wiltshire, SP4 OJQ, UK. [email protected]
,
Petra CF Oyston Defence Science and Technology Laboratory, Porton Down, Wiltshire, SP4 OJQ, UK
&
Diane E Williamson Defence Science and Technology Laboratory, Porton Down, Wiltshire, SP4 OJQ, UK
Pages 339-352 | Published online: 10 Jan 2014

References

  • Carter J. Food: Your Miracle Medicine. Harper Collins Publishers Inc., NY, USA (1993).
  • Vetvicka V. β-glucans as immunomodulators. J. Am. Nutr. Assoc.3, 31–34 (2001).
  • Brown GD, Gordon S. Fungal β-glucans and mammalian immunity. Immunity19, 311–315 (2003).
  • Yun CH, Estrada A, Van Kessel A, Park BC, Laarveld B. β-glucan, extracted from oat, enhances disease resistance against bacterial and parasitic infections. FEMS Immunol. Med. Microbiol.35, 67–75 (2003).
  • Gordon M, Bihari B, Goosby E et al. A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a Phase I/II trial. J. Med.29, 305–330 (1998).
  • Vetvicka V, Terayama K, Mandeville R et al. Pilot study: orally-administered yeast β 1,3-glucan prophylactically protects against anthrax infection and cancer in mice. J. Am. Nutr. Assoc.5, 5–9 (2002).
  • Williams DL, Cook JA, Hoffmann EO, Di Luzio NR. Protective effect of glucan in experimentally induced candidiasis. J. Reticuloendothel. Soc.23, 479–490 (1978).
  • Williams DL, Yaeger RG, Pretus HA et al. Immunization against Trypanosoma cruzi: adjuvant effect of glucan. Int. J. Immunopharmacol.11, 403–410 (1989).
  • Nicolosi R, Bell SJ, Bistrian BR et al. Plasma lipid changes after supplementation with β-glucan fiber from yeast. Am. J. Clin. Nutr.70, 208–212 (1999).
  • Tam SC, Yip KP, Fung KP, Chang ST. Hypotensive and renal effects of an extract of the edible mushroom Pleurotus-sajor-caju. Life Sci.38, 1155–1161 (1986).
  • Mayell M. Maitake extracts and their therapeutic potential. Altern. Med. Rev.6, 48–60 (2001).
  • Liu F, Ooi VEC, Chang ST. Free radical scavenging activities of mushroom polysaccharide extracts. Life Sci.60, 763–771 (1997).
  • Xiao ZG, Trincado CA, Murtaugh MP. β-glucan enhancement of T cell IFN-γ response in swine. Vet. Immunol. Immunopathol.102, 315–320 (2004).
  • McIntosh M, Stone BA, Stanisich VA. Curdlan and other bacterial (1→3)-β-D-glucans. Appl. Microbiol. Biotechnol.68, 163–173 (2005).
  • Novak M, Vetvicka V. Glucans as biological response modifiers. Curr. Drug Targets Immune Endocr. Metabol.9, 67–75 (2009).
  • Yadomae T. Structure and biological activities of fungal β-1,3-glucans. Yakugaku Zasshi120, 413–431 (2000).
  • Huang HB, Ostroff GR, Lee CK et al. Distinct patterns of dendritic cell cytokine release stimulated by fungal β-glucans and Toll-like receptor agonists. Infect. Immun.77, 1774–1781 (2009).
  • Ishibashi K, Miura NN, Adachi Y, Ohno N, Yadomae T. Relationship between solubility of grifolan, a fungal 1,3-β-D-glucan, and production of tumor necrosis factor by macrophages in vitro. Biosci. Biotechnol. Biochem.65, 1993–2000 (2001).
  • Zhang M, Cheung PCK, Zhang L, Chiu CM, Ooi VEC. Carboxymethylated β-glucans from mushroom sclerotium of Pleurotus tuber-regium as novel water-soluble anti-tumor agent. Carbohydr. Polym.57, 319–325 (2004).
  • Wang YJ, Yu YZ, Mao JW. Carboxymethylated β-glucan derived from Poria cocos with biological activities. J. Agri. Food Chem.57, 10913–10915 (2009).
  • Guo Z, Hu Y, Wang D et al. Sulfated modification can enhance the adjuvanticity of lentinan and improve the immune effect of ND vaccine. Vaccine27, 660–665 (2009).
  • Allendorf DJ, Baran JT, Hansen RD et al. Orally administered β-glucan functions via anti-tumor mAbs and the complement system to recruit CR3+ neutrophils and macrophages that produce tumor regression and tumor-free survival. Mol. Immunol.40, 195–196 (2003).
  • Hong F, Hansen RD, Yan J et al. β-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res.63, 9023–9031 (2003).
  • Yiannikouris A, Andre G, Buleon A et al. Comprehensive conformational study of key interactions involved in zearalenone complexation with β-D-glucans. Biomacromolecules5, 2176–2185 (2004).
  • Zhang L, Li XL, Xu XJ, Zeng FB. Correlation between antitumor activity, molecular weight, and conformation of lentinan. Carbohydr. Res.340, 1515–1521 (2005).
  • Borchers AT, Stern JS, Hackman RM, Keen CL, Gershwin ME. Mushrooms, tumors, and immunity. Proc. Soc. Exp. Biol. Med.221, 281–293 (1999).
  • Ikeda Y, Adachi Y, Ishibashi K, Miura N, Ohno N. Activation of Toll-like receptor-mediated NF-κB by Zymosan-derived water-soluble fraction: possible contribution of endotoxin-like substances. Immunopharmacol. Immunotoxicol.27, 285–298 (2005).
  • Benacerraf B, Thorbecke GJ, Jacoby D. Effect of zymosan on endotoxin toxicity in mice. Proc. Soc. Exp. Biol. Med.100, 796–799 (1959).
  • Riggi SJ, Diluzio NR. Identification of a reticuloendothelial stimulating agent in zymosan. Am. J. Physiol.200, 297–300 (1961).
  • Brown GD, Gordon S. Immune recognition of fungal β-glucans. Cell. Microbiol.7, 471–479 (2005).
  • Lull C, Wichers, HJ, Savelkoul HFJ. Antiinflammatory and immunomodulating properties of fungal metabolites. Med. Inflamm.2005(2), 63–80 (2005).
  • Kupfahl C, Geginat G, Hof H. Lentinan has a stimulatory effect on innate and adaptive immunity against murine Listeria monocytogenes infection. Int. Immunopharmacol.6, 686–696 (2006).
  • Chen K, Weng B, Chang M et al. Direct enhancement of the phagocytic and bactericidal capability of abdominal macrophage of chicks by β-1,3–1,6-glucan. Poult. Sci.87, 2242–2249 (2008).
  • Ito K, Masuda Y, Yamasaki Y, Yokota Y, Nanba H. Maitake β-glucan enhances granulopoiesis and mobilization of granulocytes by increasing G-CSF production and modulating CXCR4/SDF-1 expression. Int. Immunopharmacol.9, 1189–1196 (2009).
  • Kasai H, He LM, Kawamura M et al. IL-12 production induced by Agaricus blazei fraction H (ABH) involves Toll-like receptor (TLR). Evid. Based Complement. Alternat. Med.1, 259–267 (2004).
  • Lin YL, Lee SS, Hou SM, Chiang BL. Polysaccharide purified from Ganoderma lucidum induces gene expression changes in human dendritic cells and promotes T helper-1 immune response in BALB/c mice. Mol. Pharmacol.70, 637–644 (2006).
  • Vetvicka V, Dvorak B, Vetvickova J et al. Orally administered marine (1→3)-β-D-glucan phycarine stimulates both humoral and cellular immunity. Int. J. Biol. Macromol.40, 291–298 (2007).
  • Harada T, Misaki A, Saito H. Curdlan – a bacterial gel-forming β-1 3-glucan. Arch. Biochem. Biophys.124, 292–300 (1968).
  • Harada T, Harada A. Curdlan and succinoglycan. In: Polysaccharides in Medical Applications. Dekker, NY, USA, 21–57 (1996).
  • Futatsuyama H, Yui T, Ogawa K. Viscometry of curdlan, a linear (1→3)-β-D-glucan, in DMSO or alkaline solutions. Biosci. Biotechnol. Biochem.63, 1481–1483 (1999).
  • Nono I, Ohno N, Masuda A, Oikawa S, Yadomae T. Oxidative-degradation of an antitumor (1–3)-β-D-glucan, grifolan. J. Pharmacobio-dyn.14, 9–19 (1991).
  • Smith PD, Smythies LE, Mosteller-Barnum M et al. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J. Immunol.167, 2651–2656 (2001).
  • Hirotani T, Lee PY, Kuwata H et al. The nuclear licB protein I κ BNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J. Immunol.174, 3650–3657 (2005).
  • Smythies LE, Sellers M, Clements RH et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest.115, 66–75 (2005).
  • Janusz MJ, Austen KF, Czop JK. Isolation of soluble yeast β-glucans that inhibit human monocyte phagocytosis mediated by β-glucan receptors. J. Immunol.137, 3270–3276 (1986).
  • Kudsk KA. Current aspects of mucosal immunology and its influence by nutrition. Am. J. Surg.183(4), 390–398 (2002).
  • Montgome PC, Rosner BR, Cohn J. Secretory antibody-response – anti-Dnp antibodies induced by dinitrophenylated type-III pneumococcus. Immunol. Commun.3, 143–156 (1974).
  • Weiszcarrington P, Grimes SR, Lamm ME. Gut-associated lymphoid tissue as source of an IgA immune-response in respiratory tissues after oral immunization and intrabronchial challenge. Cell. Immunol.106, 132–138 (1987).
  • Moore FA. Common mucosal immunity: a novel hypothesis. Ann. Surg.231, 9–10 (2000).
  • Dewitt RC, Wu Y, Renegar KB et al. Bombesin recovers gut-associated lymphoid tissue and preserves immunity to bacterial pneumonia in mice receiving total parenteral nutrition. Ann. Surg.231, 1–8 (2000).
  • Zhou L, Zhang Q, Zhang Y, Liu J, Cao Y. The shiitake mushroom-derived immuno-stimulant lentinan protects against murine malaria blood-stage infection by evoking adaptive immune-responses. Int. Immunopharmacol.9, 455–462 (2009).
  • Czop JK. The role of β-glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic-activation. Pathol. Immunopathol. Res.5, 286–296 (1986).
  • Williams DL, Mueller A, Browder W. Glucan-based macrophage stimulators – a review of their anti-infective potential. Clin. Immunother.5, 392–399 (1996).
  • Inohara N, Ogura Y, Nunez G. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr. Opin. Microbiol.5, 76–80 (2002).
  • Janeway CA, Medzhitov R. Innate immune recognition. Ann. Rev. Immunol.20, 197–216 (2002).
  • Janeway CA. The immune-system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today13, 11–16 (1992).
  • Brown GD, Gordon S. Immune recognition – a new receptor for β-glucans. Nature413, 36–37 (2001).
  • Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J. Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology42, 61–74 (1999).
  • Underhill DM, Rossnagle E, Lowell CA, Simmons RM. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood106, 2543–2550 (2005).
  • Vera J, Fenutria R, Canadas O et al. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc. Natl Acad. Sci. USA106, 1506–1511 (2009).
  • Ariizumi K, Shen GL, Shikano S et al. Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. J. Biol. Chem.275, 20157–20167 (2000).
  • McMahon CW, Raulet DH. Expression and function of NK cell receptors in CD8+ T cells. Curr. Opin. Immunol.13, 465–470 (2001).
  • Willment JA, Gordon S, Brown GD. Characterization of the human β-glucan receptor and its alternatively spliced isoforms. J. Biol. Chem.276, 43818–43823 (2001).
  • Brown GD, Taylor PR, Reid DM et al. Dectin-1 is a major β-glucan receptor on macrophages. J. Exp. Med.196, 407–412 (2002).
  • Adams EL, Rice PJ, Graves B et al. Differential high-affinity interaction of dectin-1 with natural or synthetic glucans is dependent upon primary structure and is influenced by polymer chain length and side-chain branching. J. Pharmacol. Exp. Ther.325, 115–123 (2008).
  • Hida TH, Ishibashi K, Miura NN et al. Cytokine induction by a linear 1,3-glucan, curdlan-oligo, in mouse leukocytes in vitro. Inflamm. Res.58, 9–14 (2009).
  • Dennehy KM, Ferwerda G, Faro-Trindade I et al. Syk kinase is required for collaborative cytokine production induced through dectin-1 and Toll-like receptors. Eur. J. Immunol.38, 500–506 (2008).
  • Goodridge HS, Wolf AJ, Underhill DM. β-glucan recognition by the innate immune system. Immunol. Rev.230, 38–50 (2009).
  • Gross O, Gewies A, Finger K et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature442, 651–656 (2006).
  • Leibund Gut-Landmann S, Gross O, Robinson MJ et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol.8, 630–638 (2007).
  • Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med.197, 1107–1117 (2003).
  • Dennehy KM, Brown GD. The role of the β-glucan receptor dectin-1 in control of fungal infection. J. Leuk. Biol.82, 253–258 (2007).
  • Tsoni SV, Brown GD. β-glucans and dectin-1. Ann. NY Acad. Sci.1143, 45–60 (2008).
  • Reid D, Gow NAR, Brown G. Pattern recognition: recent insights from dectin-1. Curr. Opin. Immunol.21, 30–37 (2009).
  • Dennehy K, Willment J, Williams D, Brown G. Reciprocal regulation of IL-23 and IL-12 following co-activation of dectin-1 and TLR signaling pathways. Eur. J. Immunol.39, 1379–1386 (2009).
  • Lyakh L, Cardone M, Riboldi E, Trinchieri G. Regulation of IL-1 β and IL-23 production by β-glucan in human dendritic cells. J. Immunol.182, 135–176 (2009).
  • Ezekowitz RAB, Sim RB, Hill M, Gordon S. Local opsonization by secreted macrophage complement components – role of receptors for complement in uptake of zymosan. J. Exp. Med.159, 244–260 (1984).
  • Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ. Specificity of membrane complement receptor type 3 (Cr3) for β-glucans. Complement4, 61–74 (1987).
  • Ross GD. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/α(M)β(2)-integrin glycoprotein. Crit. Rev. Immunol.20, 197–200 (2000).
  • Xia Y, Ross GD. Generation of recombinant fragments of CD11b expressing the functional β-glucan-binding lectin site of CR3 (CD11b/CD18). J. Immunol.162, 7285–7293 (1999).
  • Li B, Allendorf DJ, Hansen R et al. Yeast β-glucan amplifies phagocyte killing of iC3β-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J. Immunol.177, 1661–1669 (2006).
  • Chan GCF, Chan WK, Sze DMY. The effects of β-glucan on human immune and cancer cells. J. Hematol. Oncol.2, 25 (2009).
  • Chen JZ, Seviour R. Medicinal importance of fungal β-(1→3), (1→6)-glucans. Mycol. Res.111, 635–652 (2007).
  • Rice PJ, Kelley JL, Kogan G et al. Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-β-D-glucans. J. Leuk. Biol.72, 140–146 (2002).
  • Means TK, Mylonakis E, Tampakakis E et al. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J. Exp. Med.206, 637–653 (2009).
  • Vereschagin EI, van Lambalgen AA, Dushkin MI et al. Soluble glucan protects against endotoxin shock in the rat: the role of the scavenger receptor. Shock9, 193–198 (1998).
  • Lee JN, Lee DY, Ji IH et al. Purification of soluble β-glucan with immune-enhancing activity from the cell wall of yeast. Biosci. Biotechnol. Biochem.65, 837–841 (2001).
  • Sakurai T, Ohno N, Yadomae T. Effects of fungal β-glucan and interferon-γ on the secretory functions of murine alveolar macrophages. J. Leuk. Biol.60, 118–124 (1996).
  • Hunter KW, duPre’ S, Redelman D. Microparticulate β-glucan upregulates the expression of B7.1, B7.2, B7-H1, but not B7-DC on cultured murine peritoneal macrophages. Immunol. Lett.93, 71–78 (2004).
  • Adachi Y, Okazaki M, Ohno N, Yadomae T. Enhancement of cytokine production by macrophages stimulated with (1→3)-β-D-glucan, grifolan (Grn), isolated from Grifola frondosa. Biol. Pharm. Bull.17, 1554–1560 (1994).
  • Olson EJ, Standing JE, GriegoHarper N, Hoffman OA, Limper AH. Fungal β-glucan interacts with vitronectin and stimulates tumor necrosis factor a release from macrophages. Infect. Immun.64, 3548–3554 (1996).
  • Engstad CS, Engstad RE, Olsen JO, Osterud B. The effect of soluble β-1,3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood. Int. Immunopharmacol.2(11), 1585–1597 (2002).
  • Tsukada C, Yokoyama H, Miyaji C et al. Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of β-glucan. Cell. Immunol.221, 1–5 (2003).
  • Shen JW, Ren HW, Tomiyama-Miyaji C et al. Potentiation of intestinal immunity by micellary mushroom extracts. Biomed. Res.28, 71–77 (2007).
  • Suzuki I, Hashimoto K, Ohno N, Tanaka H, Yadomae T. Immunomodulation by orally-administered β-glucan in mice. Int. J. Immunopharmacol.11, 761–769 (1989).
  • Hunter KW, Gault RA, Berner MD. Preparation of microparticulate β-glucan from Saccharomyces cerevisiae for use in immune potentiation. Lett. Appl. Microbiol.35, 267–271 (2002).
  • Suzuki I, Tanaka H, Kinoshita A et al. Effect of orally-administered β-glucan on macrophage function in mice. Int. J. Immunopharmacol.12, 675–684 (1990).
  • Vetvicka V, Vashishta A, Saraswat-Ohri S, Vetvickova J. Immunological effects of yeast- and mushroom-derived β-glucans. J. Med. Food11, 615–622 (2008).
  • Kournikakis B, Mandeville R, Brousseau P, Ostroff G. Anthrax-protective effects of yeast b 1,3 glucans. MedGenMed5(1), 1 (2003).
  • Sakurai T, Suzuki I, Kinoshita A et al. Effect of intraperitoneally administered β-1,3-glucan, Ssg, obtained from Sclerotinia sclerotiorum Ifo-9395 on the functions of murine alveolar macrophages. Chem. Pharm. Bull.39, 214–217 (1991).
  • Rice PJ, Adams EL, Ozment-Skelton T et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J. Pharmacol. Exp. Ther.314, 1079–1086 (2005).
  • White TR, Thompson RCA, Penhale WJ, Chihara G. The effect of lentinan on the resistance of mice to Mesocestoides corti. Parasitol. Res.74, 563–568 (1988).
  • Altuwaijri AS, Mahmoud AA, Almofleh IA, Alkhuwaitir SA. Effect of glucan on Leishmania major infection in Balb/C mice. J. Med. Microbiol.23, 363–365 (1987).
  • Kumar P, Ahmad S. Glucan-induced immunity in mice against Plasmodium berghei. Ann. Trop. Med. Parasitol.79, 211–213 (1985).
  • Havlik I, Looareesuwan S, Vannaphan S et al. Curdlan sulphate in human severe/cerebral Plasmodium falciparum malaria. Trans. Royal Soc. Trop. Med. Hyg.99, 333–340 (2005).
  • Bousquet M, Escoula L, Pipy B et al. 2 β-1–3, β-1–6 polysaccharides (Psat and scleroglucan) induce enhancement of the resistance of mice to Toxoplasma gondii. Ann. Parasitol. Hum. Comp.63, 398–409 (1988).
  • Yun CH, Estrada A, Van Kessel A et al. Immunomodulatory effects of oat β-glucan administered intragastrically or parenterally on mice infected with Eimeria vermiformis. Microbiol. Immunol.42, 457–465 (1998).
  • Wasser S, Weis A. Medicinal properties of substances occurring in higher basidiomycetes mushrooms: current perspectives (review). Int. J. Med. Mushrooms1, 31–62 (1999).
  • Hetland G, Lovik M, Wiker HG. Protective effect of β-glucan against Mycobacterium bovis, BCG infection in BALB/c mice. Scand. J. Immunol.47, 548–553 (1998).
  • Liang JS, Melican D, Cafro L et al. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int. J. Immunopharmacol.20, 595–614 (1998).
  • Dritz SS, Shi J, Kielian TL et al. Influence of dietary β-glucan on growth-performance, nonspecific immunity, and resistance to Streptococcus suis infection in weanling pigs. J. Anim. Sci.73, 3341–3350 (1995).
  • Rasmussen LT, Seljelid R. Dynamics of blood components and peritoneal fluid during treatment of murine Escherichia coli sepsis with β-1,3-D-polyglucose derivatives. I. Cells. Scand. J. Immunol.32, 321–331 (1990).
  • Delville J, Jacques PJ. Therapeutic effect of yeast glucan in mice infected with Mycobacterium leprae. Arch. Int. Physiol. Biochim. Biophys.85, 965–966 (1977).
  • Sullivan R, Smith JE, Rowan NJ. Medicinal mushrooms and cancer therapy – translating a traditional practice into Western medicine. Persp. Biol. Med.49, 159–170 (2006).
  • Kimura Y, Tojima H, Fukase S, Takeda K. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol. Suppl.511, 192–195 (1994).
  • Wasser S, Nevo E, Sokolov D, Reshetnikov S, Timor-Tismenetsky M. Dietary supplements from medicinal mushrooms: diversity of types and variety of regulations. Int. J. Med. Mushrooms2, 1–19 (2000).
  • Babicek K, Cechova I, Simon RR, Harwood M, Cox DJ. Toxicological assessment of a particulate yeast (1,3/1,6)-β-D-glucan in rats. Food Chem. Toxicol.45, 1719–1730 (2007).
  • Takahashi H, Ohno N, Adachi Y, Yadomae T. Association of immunological disorders in lethal side effect of NSAIDs on β-glucan-administered mice. FEMS Immunol. Med. Microbiol.31, 1–14 (2001).
  • Nameda S, Miura NN, Adachi Y, Ohno N. Antibiotics protect against septic shock in mice administered β-glucan and indomethacin. Microbiol. Immunol.51, 851–859 (2007).
  • Vetvicka V, Vetvickova J. β-glucan–indomethacin combination produces no lethal effects. Biomed. Papers153, 111–116 (2009).
  • Bowers GJ, Patchen ML, Macvittie TJ, Hirsch EF, Fink MP. A comparative evaluation of particulate and soluble glucan in an endotoxin model. Int. J. Immunopharmacol.8, 313–321 (1986).
  • Hetland G, Ohno N, Aaberge IS, Lovik M. Protective effect of β-glucan against systemic Streptococcus pneumoniae infection in mice. FEMS Immunol. Med. Microbiol.27, 111–116 (2000).
  • Cook JA, Dougherty WJ, Holt TM. Enhanced sensitivity to endotoxin induced by the restimulant, glucan. Circulat. Shock7, 225–238 (1980).
  • Jones ML, Warren JS. Monocyte chemoattractant protein-1 in a rat model of pulmonary granulomatosis. Lab. Invest.66, 498–503 (1992).
  • Zekovic DB, Kwiatkowski S, Vrvic MM, Jakovljevic D, Moran CA. Natural and modified (1→3)-β-D-glucans in health promotion and disease alleviation. Crit. Rev. Biotechnol.25, 205–230 (2005).
  • Valdes-Ramos R, Itez-Arciniega AD. Nutrition and immunity in cancer. Br. J. Nutr.98, S127–S132 (2007).
  • LeBlanc BW, Albina JE, Reichner JS. The effect of PGG-β-glucan on neutrophil chemotaxis in vivo. J. Leuk. Biol.79, 667–675 (2006).
  • Tari K, Satake I, Nakagomi K et al. [Effect of lentinan for advanced prostate carcinoma]. Hinyokika Kiyo40, 119–123 (1994).
  • Nakano H, Namatame K, Nemoto H et al. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Hepatogastroenterology46, 2662–2668 (1999).
  • Fujimoto S. [Clinical efficacies of schizophyllan (SPG) on advanced gastric cancer]. Nippon Geka Gakkai Zasshi90, 1447–1450 (1989).
  • Hamuro J. [Anticancer immunotherapy with perorally effective lentinan]. Gan. To Kagaku Ryoho32, 1209–1215 (2005).
  • Yoshino S, Oka M. [Clinical trial of non-specific immunotherapy using Lentinan in advanced or recurrent gastric cancer]. Gan. To Kagaku Ryoho35, 2239–2243 (2008).
  • Yang P, Liang MH, Zhang YX, Shen BZ. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv. Ther.25, 787–794 (2008).
  • Defelippe J, Silva MDE, Maciel FMB, Soares AD, Mendes NF. Infection prevention in patients with severe multiple trauma with the immunomodulator β-1–3 polyglucose (glucan). Surg. Gynecol. Obstet.177, 383–388 (1993).
  • Babineau TJ, Hackford A, Kenler A et al. A Phase-II multicenter, double-blind, randomized, placebo-controlled study of 3 dosages of an immunomodulator(Pgg-glucan) in high-risk surgical patients. Arch. Surg.129, 1204–1210 (1994).
  • Babineau TJ, Marcello P, Swails W et al. Randomized Phase I/II trial of a macrophage-specific immunomodulator (Pgg-glucan) in high-risk surgical patients. Ann. Surg.220, 601–609 (1994).
  • Dellinger EP, Babineau TJ, Bleicher P et al. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Arch. Surg.134, 977–983 (1999).
  • Gordon M, Guralnik M, Kaneko Y et al. Further clinical studies of curdlan sulfate (Crds) – an anti-HIV agent. J. Med.26, 97–131 (1995).
  • Gordon M, Guralnik M, Kaneko Y et al. A Phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (DDI) in HIV patients with CD4 cells of 200–500/mm3. J. Med.26, 193–207 (1995).
  • Gordon M, Deeks S, DeMarzo C et al. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: anti-CMV activity with low toxicity. J. Med.28, 108–128 (1997).
  • Nieman DC, Henson DA, McMahon M et al. β-glucan, immune function, and upper respiratory tract infections in athletes. Med. Sci. Sports Exerc.40, 1463–1471 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.